Innovative research published in Nature Biotechnology describes antibody–bottlebrush prodrug conjugates that expand payload diversity beyond conventional antibody–drug conjugates (ADCs). These prodrugs enable high drug-to-antibody ratios and modular design, incorporating lower potency agents with favorable preclinical efficacy and safety profiles. This platform addresses limitations of traditional ADCs, promising enhanced therapeutic specificity and reduced off-target toxicity in cancer treatment.